Tata Steel optimistic about demand for steel in 2021: CEO TV Narendran

TV Narendran, MD and CEO of Tata Steel, said the steel demand in the country should grow at least at the rate of GDP growth or higher in FY22.

Moneycontrol News

December 31, 2020 / 02:27 PM IST

Tata Steel

Despite the COVID-19 pandemic and the emergence of a new strain, Tata Steel is confident that there will be a rise in demand for steel in India in 2021.

"We are seeing an inflow of funds from across sectors and an uptick in the overall consumption. The government’s efforts of improving infrastructure, coupled with the ‘Atmanirbhar Bharat’ policy and Production Linked Incentive Scheme (PLI), are expected to further boost this inflow,” MD and CEO of Tata Steel, TV Narendran, said on December 31 via a company statement.

Additionally, the government’s focus on rural infrastructure projects will also give an impetus to steel demand, he added.

"We believe that the steel demand in the country should grow at least at the rate of GDP growth or higher in FY22,” Narendran said.

On steel prices, he said that globally, prices were likely to stay firm as China was not expected to export large volumes owing to a better balance in their domestic market, and there were no other very significant exporters in the world market.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show